从指南到实践:西澳全科医生对初级保健中特定多病共存管理指标达成共识
本研究采用两轮改良德尔菲法,对西澳21名全科医生进行调查,旨在就2型糖尿病、肥胖、高血压、心血管疾病和慢性肾脏病五种常见慢性病的管理依从性指标达成共识。第二轮结束时,61项指标达成共识,大多数指标清晰度良好,但涉及CKD合并T2DM的药物治疗的两项指标需要更明确的指导。该研究首次将疾病特异性指标整合为全科医生参与制定的多病共存管理工具,值得进一步试点评估。
要点
- 21名西澳全科医生通过两轮德尔菲法就61项多病共存管理指标达成共识。
- 共识指标覆盖生物物理标志物、生活方式风险和药物治疗管理。
- 两项关于CKD合并T2DM药物治疗的指标清晰度不足,需更明确指导。
核心结论
- 全科医生对五种常见慢性病的管理依从性指标达成强共识,支持该工具用于多病共存整体管理。
研究设计与样本
- 两轮改良德尔菲调查,遵循RAND方法,纳入21名西澳全科医生。
- 指标来源于澳大利亚皇家全科医师学院指南,涵盖生物物理标志物、生活方式风险和药物治疗管理。
- 采用4点Likert量表(无中性选项)评价指标的相关性和清晰度。
主要发现
- 第一轮57项指标达成相关性共识,并新增4项建议指标。
- 第二轮结束时共61项指标达成共识。
- 大多数指标被评为清晰,但两项涉及CKD合并T2DM药物治疗的指标需要更清晰的指导。
- 反馈强调需要细化血脂管理指南、优先考虑肥胖管理以预防疾病,以及生活方式咨询存在挑战。
关键数值与推荐
- 共识定义为至少70%的全科医生对指标的相关性评分≥3。
- 当至少80%的指标达到该阈值且无新条目提出时结束流程。
临床怎么用
- 该共识工具可用于全科医生在多病共存管理中对指南依从性的自我评估或质量改进。
- 针对CKD合并T2DM的药物治疗指标需结合更明确的指导使用。
- 血脂管理和肥胖预防管理应作为多病共存管理的重点改进方向。
局限性
- 仅纳入西澳21名全科医生,样本量小且地域局限。
- 共识基于全科医生主观评分,未验证对患者结局的影响。
- 尚未进行试点评估其对指南依从性和患者结局的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multimorbidity is rising in primary care, yet adherence to guidelines is hindered by fragmented, disease-specific recommendations. This study sought to establish consensus among general practitioners (GPs) on indicators of adherence to Australian guidelines in managing five common chronic conditions [type 2 diabetes mellitus (T2DM), obesity, hypertension, cardiovascular disease, and chronic kidney disease (CKD)], aiming to develop a unified tool for holistic care. METHODS: A two-round reactive Delphi survey was conducted with 21 GPs in Western Australia, following RAND methodology. Indicators were drawn from the Royal Australian College of General Practitioners' guidelines and covered biophysical markers, lifestyle risks, and pharmacological management. Participants rated indicators for relevance and clarity on a 4-point Likert scale without a neutral option. Consensus was defined as ≥70% of GPs rating an indicator ≥3 for mean relevance. The process ended when ≥80% of indicators reached this threshold, and no new items were proposed. Feedback refined wording and, where relevant, was reported verbatim. RESULTS: In Round 1, 57 indicators achieved consensus on relevance, with four additional items suggested. By Round 2, consensus was reached on 61 indicators. Most were rated clear, except two addressing pharmacological management of CKD with T2DM, which require clearer guidance. Feedback emphasized the need for refined lipid management guidelines, prioritizing obesity management for prevention, and challenges in lifestyle counselling. CONCLUSION: This study represents the first integration of disease-specific indicators into a GP-informed tool for multimorbidity management. Strong consensus highlights its practicality, warranting piloting to evaluate effects on guideline adherence and patient outcomes.
引用
- Ishimwe SMC, Carey TA, Affandi JS, et al. From guidelines to practice: general practitioners' consensus on indicators for managing selected multimorbidity in primary care in Western Australia. Fam Pract. 2026. PMID: 42485647. doi:10.1093/fampra/cmag055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。